Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men

Plain-language summary

Published 2024 in Endocr J, this work by Yamaguchi S and collaborators tackles a specific question within safety-focused NMN/NAD+ research.

Key findings reported by the authors

• Mechanistic study in Endocr J (2024) on NAD+/sirtuin/longevity biology
• Adds to the foundational literature underlying NMN supplementation rationale
• First author: Yamaguchi S

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to safety decisions, with secondary relevance to benefits and science. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.